PARK MEDI WORLD LIMITED (PARKHOSPS) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of PARK MEDI WORLD LIMITED ₹242, price ₹271, upside -10.8%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch PARK MEDI WORLD LIMITED for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 2, 2026.
How to read this chart
9‑month range ₹143.92 – ₹299.30 · fair‑value band ₹140.42 – ₹328.68 · the ₹270.80 price screens above the ₹241.68 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 2, 2026.
Follow PARK MEDI WORLD in your weekly email
Every Wednesday you see whether PARK MEDI WORLD is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Park Medi World Limited operates a network of hospitals.
Show more
Park Medi World Limited operates a network of hospitals. The company provides cardiac sciences, neurosciences - brain and spine, plastic and cosmetic surgery, general and laparoscopic surgery, renal sciences and kidney transplant, bone, orthopaedics, joint replacement and sports medicine, gastroenterology and surgical gastroenterology, cancer care, bone marrow transplant, iMARS / robot-assisted surgery. It also offers bariatric surgery, anaesthesiology, critical care, chest and respiratory diseases, dental care, dermatology, endocrinology, paediatrics, internal medicine and geriatrics, rheumatology, ENT, ophthalmology, obstetrics and gynaecology, interventional radiology and imaging, psychiatry, pathology and microbiology, paediatric surgery, fertility management, nuclear medicine services. It operates NABH accredited multi-super specialty hospitals under the Park brand name. Park Medi World Limited was founded in 2005 and is headquartered in Gurugram, India.
Stock analysis
PARK MEDI WORLD LIMITED (PARKHOSPS) currently trades at ₹270.80, while our model-based Fair Value estimate is ₹241.68, 10.8% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹139.49 per share, and 0 of the 24 models we run sit above the ₹270.80 price.
Bear case: the Asset-Based group reads lowest at ₹31.36, and 24 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: ₹140.42 (bear) to ₹328.68 (bull), the price of ₹270.80 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
PARK MEDI WORLD LIMITED reported revenue of ₹16.8B in FY2026 versus ₹12.5B in FY2023, a compound +10.3%/yr. Reported net income was ₹2.6B in FY2026, compounding +5.5%/yr from FY2023.
Key figures
Market cap ₹117B (≈ $1.2B) · P/E ratio 41.4 · P/S ratio 6.36 · EPS (TTM) ₹6.54 · Net margin 15.4% · Return on equity 16.9% · Return on assets (EBIT) 16.4% · Operating margin 22.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −11%, PARKHOSPS screens richer than that median.
Fair Value models
Bear ₹140.42Fair Value ₹241.68Bull ₹328.68
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹3.31 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.92/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+20.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
’23
’24
’25
’26
What shareholders gained per year (last 3 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+11.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+11.4%
Dividend (yield on the price)0.0%
Profit margin 2023 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.30% → 23%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+40.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +35.0% a year for the price.
Compare PARK MEDI WORLD LIMITED with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 244 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score61 · Above median
Fair Value upside−10.8% · Below median
Profitability
Return on equity (TTM)16.9% · Top 25%
Return on assets9.7% · Top 25%
Net margin (TTM)15.4% · Top 25%
Operating margin (TTM)23.9% · Top 25%
Growth and dividend
Revenue growth30.1% · Top 25%
Balance sheet
Debt / equity0.01× · Lowest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "PARK MEDI WORLD LIMITED Fair Value". https://www.fairvalue-calculator.com/stock/PARKHOSPS
Frequently asked questions
Is PARK MEDI WORLD LIMITED (PARKHOSPS) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of ₹241.68 versus a price of ₹270.80, about −11% upside (overvalued).
What is the fair value of PARKHOSPS?
Our model-based fair value for PARK MEDI WORLD LIMITED is ₹241.68 (as of Oct 2, 2026), built from audited fundamentals. The current price: ₹270.80.
What is the quality score of PARKHOSPS?
PARK MEDI WORLD LIMITED has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PARK MEDI WORLD LIMITED (PARKHOSPS)?
Our model-based price target is the fair value of ₹241.68 (as of Oct 2, 2026) from 24 valuation models. Cautious scenario ₹140.42, optimistic scenario ₹328.68. It is a calculation from audited fundamentals, not an analyst target.
What is the PARK MEDI WORLD LIMITED stock forecast for 2026?
Our models put fair value at ₹241.68, about −11% upside versus a price of ₹270.80 (overvalued). Cautious scenario ₹140.42, optimistic scenario ₹328.68. The calculation is refreshed regularly with new filings.
What is the revenue of PARK MEDI WORLD LIMITED (PARKHOSPS)?
PARK MEDI WORLD LIMITED reported trailing-twelve-month revenue of about ₹17.6B (latest available figure, as of Oct 2, 2026).
What growth is priced into PARK MEDI WORLD LIMITED (PARKHOSPS)?
For today's price to be fair in a discounted-cash-flow model, PARK MEDI WORLD LIMITED would have to grow free cash flow by +40.6 % per year for five years (discount rate 13.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +10.3 % per year. As of Oct 2, 2026.
What discount rate (WACC) does the fair value of PARKHOSPS use?
Our models discount PARK MEDI WORLD LIMITED at 13.9 %: a base by market capitalisation (small), country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For PARK MEDI WORLD LIMITED that is +40.6 % per year a year over ten years, using the same discount rate (13.9 %) and the same formula as our fair value.
How much growth has PARK MEDI WORLD LIMITED (PARKHOSPS) delivered so far?
Over the past 3 years revenue at PARK MEDI WORLD LIMITED grew +10.3 % a year. The price currently implies +40.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of PARK MEDI WORLD LIMITED (PARKHOSPS) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into PARK MEDI WORLD LIMITED (+40.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of PARK MEDI WORLD LIMITED (PARKHOSPS)?
The free-cash-flow yield on the price is 1.79 %: that much free cash flow PARK MEDI WORLD LIMITED produces per unit of market value. When it exceeds the discount rate of our models (13.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of PARK MEDI WORLD LIMITED (PARKHOSPS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PARK MEDI WORLD LIMITED it is ₹241.68 per share (as of Oct 2, 2026), against a price of ₹270.80. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is PARK MEDI WORLD LIMITED stock overvalued or undervalued in 2026?
As of Oct 2, 2026, PARKHOSPS trades above its calculated fair value: price ₹270.80, fair value ₹241.68, a gap of about −11% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PARKHOSPS?
No. The price is what the market pays today (₹270.80); the fair value is what the company's own numbers justify (₹241.68). For PARK MEDI WORLD LIMITED the two are ₹29.12 per share apart. That gap is exactly why we show both numbers side by side.
How much is PARK MEDI WORLD LIMITED worth?
The market values PARK MEDI WORLD LIMITED at about ₹117B (market capitalisation, as of Oct 2, 2026). Per share that is ₹270.80; our models calculate a fair value of ₹241.68 per share.
What do the bullish and bearish scenarios say about PARKHOSPS?
Our models span a range for PARK MEDI WORLD LIMITED: cautious scenario ₹140.42, base ₹241.68, optimistic ₹328.68 per share (as of Oct 2, 2026, price ₹270.80). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PARKHOSPS?
PARK MEDI WORLD LIMITED trades at a price-to-earnings ratio of 41.4 (as of Oct 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹241.68 is built from several models across several years. Other multiples: P/B 5.8, P/S 7.0, EV/EBITDA 25.8.
How solid is the balance sheet of PARK MEDI WORLD LIMITED (PARKHOSPS)?
Balance-sheet figures for PARK MEDI WORLD LIMITED (as of Oct 2, 2026): return on equity 16.9%, debt of 0.01 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
Which stocks are comparable to PARK MEDI WORLD LIMITED?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PARK MEDI WORLD LIMITED stock attractive at the current price?
The data as of Oct 2, 2026: price ₹270.80, calculated fair value ₹241.68 (−11%), Quality Score 60/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PARKHOSPS calculated?
We run PARK MEDI WORLD LIMITED through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹241.68, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. PARK MEDI WORLD LIMITED itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PARK MEDI WORLD LIMITED (PARKHOSPS)?
The closing price on Oct 1, 2026 was ₹270.80. Our model-based fair value is ₹241.68, about −11% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PARK MEDI WORLD LIMITED right now?
A fairly wide model range (₹140.42 to ₹328.68) leaves room in how you read the outcome. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of PARK MEDI WORLD LIMITED
How large is the market capitalisation of PARK MEDI WORLD LIMITED (PARKHOSPS)?
The market capitalisation of PARK MEDI WORLD LIMITED is ₹117B (≈ $1.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PARK MEDI WORLD LIMITED (PARKHOSPS)?
The price-to-sales ratio of PARK MEDI WORLD LIMITED is 6.36 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of PARK MEDI WORLD LIMITED (PARKHOSPS)?
Earnings per share at PARK MEDI WORLD LIMITED are ₹6.54 (price ÷ EPS = P/E 41.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of PARK MEDI WORLD LIMITED (PARKHOSPS)?
The net margin of PARK MEDI WORLD LIMITED is 15.4% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PARK MEDI WORLD LIMITED (PARKHOSPS)?
The return on equity (ROE) of PARK MEDI WORLD LIMITED is 16.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PARK MEDI WORLD LIMITED (PARKHOSPS)?
On an EBIT basis the return on assets of PARK MEDI WORLD LIMITED is 16.4% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PARK MEDI WORLD LIMITED (PARKHOSPS)?
The operating margin of PARK MEDI WORLD LIMITED is 22.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PARK MEDI WORLD LIMITED (PARKHOSPS)?
Revenue at PARK MEDI WORLD LIMITED is growing +19.3% versus a year earlier (3y avg +10.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at PARK MEDI WORLD LIMITED (PARKHOSPS)?
Earnings per share at PARK MEDI WORLD LIMITED are growing +20.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does PARK MEDI WORLD LIMITED (PARKHOSPS) carry?
The net debt of PARK MEDI WORLD LIMITED is ₹5.2B (fiscal year 2025, ≈ 2.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch PARK MEDI WORLD LIMITED in the live analysis
One click puts PARK MEDI WORLD LIMITED on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
